ALX Oncology (ALXO) Competitors $0.55 +0.04 (+8.76%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.54 -0.01 (-1.87%) As of 04/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALXO vs. CGEN, NKTX, CYBN, PROC, EPRX, TLSA, ELUT, FATE, ALEC, and MCRBShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Compugen (CGEN), Nkarta (NKTX), Cybin (CYBN), Procaps Group (PROC), Eupraxia Pharmaceuticals (EPRX), Tiziana Life Sciences (TLSA), Elutia (ELUT), Fate Therapeutics (FATE), Alector (ALEC), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Compugen Nkarta Cybin Procaps Group Eupraxia Pharmaceuticals Tiziana Life Sciences Elutia Fate Therapeutics Alector Seres Therapeutics Compugen (NASDAQ:CGEN) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking. Which has higher valuation and earnings, CGEN or ALXO? Compugen has higher revenue and earnings than ALX Oncology. Compugen is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompugen$27.86M4.42-$18.75M-$0.16-8.63ALX OncologyN/AN/A-$160.80M-$2.60-0.21 Does the MarketBeat Community prefer CGEN or ALXO? Compugen received 254 more outperform votes than ALX Oncology when rated by MarketBeat users. However, 64.71% of users gave ALX Oncology an outperform vote while only 64.24% of users gave Compugen an outperform vote. CompanyUnderperformOutperformCompugenOutperform Votes30964.24% Underperform Votes17235.76% ALX OncologyOutperform Votes5564.71% Underperform Votes3035.29% Which has more risk & volatility, CGEN or ALXO? Compugen has a beta of 3.19, meaning that its stock price is 219% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Is CGEN or ALXO more profitable? Compugen has a net margin of 2.67% compared to ALX Oncology's net margin of 0.00%. Compugen's return on equity of 2.62% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Compugen2.67% 2.62% 1.36% ALX Oncology N/A -93.02%-70.67% Do institutionals & insiders have more ownership in CGEN or ALXO? 12.2% of Compugen shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 33.4% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor CGEN or ALXO? In the previous week, Compugen had 1 more articles in the media than ALX Oncology. MarketBeat recorded 2 mentions for Compugen and 1 mentions for ALX Oncology. Compugen's average media sentiment score of 0.93 equaled ALX Oncology'saverage media sentiment score. Company Overall Sentiment Compugen Positive ALX Oncology Positive Do analysts rate CGEN or ALXO? Compugen presently has a consensus target price of $4.00, suggesting a potential upside of 189.86%. ALX Oncology has a consensus target price of $4.14, suggesting a potential upside of 659.35%. Given ALX Oncology's higher possible upside, analysts clearly believe ALX Oncology is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 SummaryCompugen beats ALX Oncology on 11 of the 16 factors compared between the two stocks. Remove Ads Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.11M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.186.7921.6617.82Price / SalesN/A225.97373.3994.61Price / CashN/A65.6738.1534.64Price / Book0.145.866.474.00Net Income-$160.80M$141.86M$3.20B$247.23M7 Day Performance5.11%4.50%2.86%1.45%1 Month Performance-34.32%-12.65%-8.56%-6.24%1 Year Performance-96.24%-11.06%10.58%0.60% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.4937 of 5 stars$0.55+8.8%$4.14+659.4%-95.8%$29.11MN/A-0.1840Gap UpCGENCompugen1.8963 of 5 stars$1.26-3.8%$4.00+217.5%-29.6%$112.44M$27.86M63.0070NKTXNkarta2.6065 of 5 stars$1.56-4.3%$14.86+852.4%-80.4%$110.69MN/A-0.83140Short Interest ↓Gap DownCYBNCybin1.5316 of 5 stars$5.15-9.5%$86.00+1,569.9%N/A$110.61MN/A-1.1850PROCProcaps GroupN/A$0.95-40.3%N/A-63.5%$107.18M$409.92M0.004,900Positive NewsGap DownHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.366 of 5 stars$2.97+1.4%$10.50+253.5%+23.9%$105.87MN/A-4.1229Gap UpTLSATiziana Life Sciences1.2753 of 5 stars$0.90-4.6%N/A+62.0%$105.19MN/A0.008Positive NewsELUTElutia3.1254 of 5 stars$2.58-4.8%$9.00+248.8%-26.5%$105.10M$24.38M-0.99180Short Interest ↑Gap DownFATEFate Therapeutics3.4935 of 5 stars$0.91+20.8%$5.43+496.9%-80.1%$104.22M$13.63M-0.55550ALECAlector3.4925 of 5 stars$1.01-1.0%$3.50+246.5%-80.9%$100.08M$100.56M-0.59270Gap DownMCRBSeres Therapeutics3.0442 of 5 stars$0.57-10.6%$4.00+598.8%-25.2%$99.80M$126.33M-2.49330Gap Down Remove Ads Related Companies and Tools Related Companies Compugen Competitors Nkarta Competitors Cybin Competitors Procaps Group Competitors Eupraxia Pharmaceuticals Competitors Tiziana Life Sciences Competitors Elutia Competitors Fate Therapeutics Competitors Alector Competitors Seres Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALXO) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALXO Stock Free ALXO Stock Alerts